The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021 Jun; 50(3): 313–319.
PMCID: PMC8710260

Language: Chinese | English

妊娠糖尿病孕妇孕中期口服葡萄糖耐量试验异常项数及孕期增重与不良妊娠结局的关系

Relationship of abnormal mid-term oral glucose tolerance test and maternal weight gain with adverse pregnancy outcomes in women with gestational diabetes mellitus

Yunyan CHEN

1.浙江大学医学院附属妇产科医院产科,浙江 杭州 310006 2.浙江省湖州市妇幼保健院产科,浙江 湖州 313000

Find articles by Yunyan CHEN

Qi WU

1.浙江大学医学院附属妇产科医院产科,浙江 杭州 310006

Find articles by Qi WU

Lixia ZHANG

1.浙江大学医学院附属妇产科医院产科,浙江 杭州 310006

Find articles by Lixia ZHANG

Danqing CHEN

1.浙江大学医学院附属妇产科医院产科,浙江 杭州 310006

Find articles by Danqing CHEN

Zhaoxia LIANG

1.浙江大学医学院附属妇产科医院产科,浙江 杭州 310006 1.浙江大学医学院附属妇产科医院产科,浙江 杭州 310006 2.浙江省湖州市妇幼保健院产科,浙江 湖州 313000

第一作者:陈云燕,副主任医师,主要从事产科学研究;E-mail:94510670@qq.com;https://orcid.org/0000-0003-4917-8566
通信作者:梁朝霞,主任医师,博士生导师,主要从事产科学研究;E-mail: nc.ude.ujz@iaziazoaix ;https://orcid.org/0000-0002-1039-4686 P <0.017);血糖二项指标异常的孕妇妊娠期高血压疾病和早产发生率也高于一项指标异常的孕妇(均 P <0.017)。孕期增重过多孕妇妊娠期高血压疾病、巨大胎儿发生率高于增重不足和增重适宜孕妇,LGA发生率高于增重不足孕妇(均 P <0.017);增重适宜孕妇早产和低体重儿发生率低于增重不足和增重过多孕妇,小于胎龄儿(SGA)发生率低于增重不足孕妇(均 P <0.017)。在OGTT血糖一项指标异常的孕妇中,孕期增重不足是发生早产、SGA的危险因素( aOR =1.66,95% CI :1.10~2.52; aOR =2.20,95% CI :1.07~4.53),是LGA的保护因素( aOR =0.40,95% CI :0.27~0.50);孕期增重过多则是妊娠期高血压疾病、早产、低体重儿的危险因素( aOR =2.15,95% CI :1.35~3.41; aOR =1.80,95% CI :1.20~2.72; aOR =2.18,95% CI :1.10~4.30)。在OGTT血糖二项指标异常的孕妇中,孕期增重不足是巨大胎儿和LGA的保护因素( aOR =0.24,95% CI :0.09~0.67; aOR =0.54,95% CI :0.34~0.86),孕期增重过多则是早产的危险因素( aOR =1.98,95% CI :1.23~3.18)。而在OGTT血糖三项指标异常的孕妇中,孕期增重与不良妊娠结局的发生无明显关联。

结论:

在GDM孕期管理中,对于OGTT一项或两项血糖升高者,孕期体重合理管理可降低部分不良妊娠结局的发生风险;三项血糖均升高者,除了孕期体重管理,需更严格的血糖监测并进行药物降糖等积极干预措施。

Abstract

Objective:

To explore the correlation of mid-term oral glucose tolerance test (OGTT) and maternal weight gain with adverse pregnancy outcomes in women with gestational diabetes mellitus (GDM).

Methods:

A total of 2611 pregnant women with GDM who were examined and delivered in Women’s Hospital, Zhejiang University School of Medicine from July 1st 2017 to 30th June 2018 were enrolled in this study. According to the number of abnormal items of mid-term OGTT results or maternal gestational weight gain (GWG), patients were classified. The incidence of adverse perinatal outcomes in each group and its relation with OGTT results and GWG were analyzed.

Results:

The incidence of gestational hypertension, premature delivery, macrosomia and large for gestational age infant (LGA) in three abnormal items GDM patients were significantly higher than those in one or two abnormal items GDM patients (all P <0.017). The incidence of gestational hypertension and premature delivery in two abnormal items GDM patients were higher than those in one abnormal item GDM patients (all P <0.017). The incidence of gestational hypertension and macrosomia in excessive GWG patients were significantly higher than those in inadequate and appropriate GWG patients (all P <0.017), and the incidence of LGA were higher than that in inadequate GWG patients (all P <0.017). The incidence of premature delivery and low birth weight infants in appropriate GWG patients were significantly lower than those in inadequate and excessive GWG patients, and the incidence of small for gestational age infant (SGA) were significantly lower than that in inadequate GWG patients (all P <0.017). In one abnormal item GDM patients, inadequate GWG was a risk factor for premature delivery and SGA ( aOR =1.66, 95% CI : 1.10–2.52; aOR =2.20, 95% CI : 1.07–4.53), and protective factor for LGA ( aOR =0.40, 95% CI : 0.27–0.59). And excessive GWG was a risk factor for gestational hypertension, premature delivery and low birth weight infants ( aOR =2.15, 95% CI : 1.35–3.41; aOR =1.80, 95% CI : 1.20–2.72; aOR =2.18, 95% CI : 1.10–4.30).In two abnormal items GDM patients, inadequate GWG was a protective factor for macrosomia and LGA ( aOR =0.24, 95% CI : 0.09–0.67; aOR =0.54, 95% CI : 0.34–0.86), while excessive GWG was risk factor for premature delivery ( aOR =1.98, 95% CI : 1.23–3.18).In three abnormal items GDM patients, there was no significant relationship between GWG and adverse pregnancy outcomes.

Conclusion:

For GDM women with one or two items of elevated blood glucose in OGTT, reasonable weight management during pregnancy can reduce the occurrence of adverse pregnancy outcomes. For those with three items of elevated blood glucose in OGTT, more strict blood glucose monitoring and active intervention measures should be taken in addition to weight management during pregnancy.

Keywords: Gestational diabetes mellitus, Oral glucose tolerance test, Gestational weight gain, Pregnancy outcome, Health management

妊娠糖尿病(gestational diabetes mellitus,GDM);大于胎龄儿(large for gestational age infant,LGA);口服葡萄糖耐量试验(oral glucose tolerance test,OGTT);身体质量指数(body mass index,BMI);小于胎龄儿(small for gestational age infant,SGA);

GDM 是指妊娠期间首次发生或发现的糖代谢异常,是产科常见妊娠并发症。全球多中心“高血糖和不良妊娠结局”研究证实了 GDM 与 LGA、剖宫产、新生儿低血糖及高胰岛素血症等多项不良妊娠结局呈正相关 。GDM 甚至可影响母婴远期预后,如增加母亲患 2 型糖尿病以及子代发生肥胖、糖尿病、神经系统症状疾病的风险 。孕期增重不足和过多均可能增加 GDM 发生的风险,孕期增重越多,发生子痫前期、巨大胎儿、剖宫产等不良妊娠结局的风险也越高 ,可见高血糖和孕期增重对不良妊娠结局具有协同作用。本文纳入 2611 例 GDM 孕妇进行了回顾性研究,分析不同 OGTT 血糖异常项数及孕期增重与不良妊娠结局的关系,从而为 GDM 治疗提出精准及个性化的分层体重管理策略。

1对象与方法

1.1对象及分组

收集 2017 年 7 月 1 日至 2018 年 6月 30 日在浙江大学医学院附属妇产科医院定期进行产前检查并分娩的 GDM 孕妇共计 4598 例。纳入标准:①孕 24~28 周行 OGTT 且空腹、 OGTT 1 h、 OGTT 2 h血糖中至少一项异常;②单胎妊娠;③分娩孕周 28周及以上;④病历资料完整。排除标准:①合并前置胎盘、子宫畸形;②合并孕前糖尿病或慢性高血压病;③孕期服用影响血糖代谢相关药物;④合并肝肾功能不全、甲状腺疾病等其他内分泌疾病或自身免疫性疾病。最终共 2611 例 GDM 孕妇纳入研究,根据 OGTT 血糖异常项数和孕期体重增长量对孕妇进行分组。本研究通过浙江大学医学院附属妇产科医院伦理委员会审批(IRB-20210061-R)。

1.2数据收集

通过医院电子病历系统检索获取 GDM 孕妇相关信息,包括年龄、身高、孕前体重(孕前 1 个月内)、分娩前体重、孕期增重、孕产次、围产期并发症、前次妊娠分娩方式、本次妊娠分娩方式、分娩孕周、新生儿出生体重及 OGTT 空腹、OGTT 1 h、OGTT 2 h 血糖水平。根据 GDM 孕妇的身高和体重计算 BMI,即体重(kg)/[身高(m)] 2 。其中孕前体重和孕期增重资料通过回顾性方式收集,分娩前体重通过体格测量获取。

1.3相关标准及定义

GDM 的诊断标准:根据 2014 年中国《妊娠合并糖尿病诊治指南》,在妊娠 24~28 周行75 g OGTT (一步法),血糖值满足下述任意一条或多条:空腹血糖至少5.1 mmol/L;OGTT 1 h血糖至少 10.0 mmol/L;OGTT 2 h血糖至少8.5 mmol/L

美国医学研究院标准:孕前体重过轻 (BMI <18.5 kg/m 2 )者孕期增重适宜为 12.5~18.0 kg;孕前体重正常(18.5 kg/m 2 ≤BMI<25.0 kg/m 2 )者孕期增重适宜为 11.5~16.0 kg;孕前体重超重(25.0 kg/m 2 ≤BMI<30.0 kg/m 2 )者孕期增重适宜为 7.0~11.5 kg;孕前肥胖(BMI≥30.0 kg/m 2 )者孕期增重适宜为5.0~9.0 kg 。孕期增重低于或超过适宜量则分别为孕期增重不足及孕期增重过多。

不良妊娠结局的诊断参考文献 [8] :①妊娠期高血压疾病:妊娠与血压升高并存,排除妊娠合并慢性高血压者。②早产:妊娠达到 28 周但不足 37 周分娩者。③巨大胎儿:任何孕周胎儿体重超过4 kg者。④低体重儿:足月胎儿出生时体重低于2.5 kg者。⑤LGA:出生体重高于同胎龄体重第 90 百分位者。⑥SGA:出生体重低于同胎龄体重第 10 百分位者。

1.4统计学方法

采用 SPSS 22.0 软件进行统计分析。正态分布的计量资料采用均数±标准差( x ¯ ± s )表示,组间比较采用单因素方差分析,应用 LSD 进行事后多重比较( P <0.017 为差异有统计学意义);计数资料以例数和百分率[ n (%)]表示,组间比较采用 2 检验。不同 OGTT 血糖异常项数组孕期增重与不良妊娠结局相关性采用 Logistic 回归分析与叉生分析相结合,反映 OGTT 血糖异常项数及孕期增重与不良妊娠结局的交互作用。Logistic 回归分析调整空腹血糖、OGTT1 h血糖、OGTT 2 h血糖、年龄、孕次、产次、孕前 BMI 等变量。其中早产额外调整妊娠期高血压疾病、胎膜早破等变量;巨大胎儿及低体重儿额外调整妊娠期高血压疾病、分娩孕周等变量;LGA 和 SGA 额外调整妊娠期高血压疾病变量。双侧 P <0.05 为差异有统计学意义。

2结果

2.1不同 OGTT 异常项数孕妇一般特征比较

OGTT 三项均异常的孕妇年龄、经产妇比例、孕前 BMI、孕前体重超重及肥胖、孕期增重过多占比、新生儿出生体重及 OGTT 各时间点血糖水平均高于 一项和 二项指标异常的孕妇,孕周显著低于 一项和 二项指标异常的孕妇(均 P <0.017);三组平均孕期增重差异无统计学意义,见 表 l 。结果提示,OGTT 血糖异常项数与孕妇年龄、孕前 BMI、孕期增重以及 OGTT 各项血糖值相关。 不同OGTT 异常项数孕妇一般特征比较 Table 1 Comparison of general characteristics among pregnant women with different numbers of abnormal blood glucose items in OGTT x ¯ ± s n (%)]

年龄(岁)

孕次(次)

孕前 BMI(kg/m

孕前 BMI

32.1±4.4

2.3±1.3

749(49.6)

760(50.4)

21.7±3.0

183(12.1)

1141(75.6)

167(11.1)

18(1.2)

32.8±4.7

2.4±1.3

423(48.5)

449(51.5)

21.8±3.1

111(12.7)

645(74.0)

106(12.2)

10(1.2)

34.2±4.6

2.5±1.3

94(40.9)

136(59.1)

23.7±3.7

15(6.5)

140(60.9)

60(26.1)

15(6.5)

新生儿体重(g)

孕期增重(kg)

血糖水平(mmol/L)

OGTT 1 h

OGTT 2 h

38.3±1.8

3260±523

12.6±4.1

677(44.9)

567(37.6)

265 (17.6)

4.6±0.5

9.4±1.2

8.3±1.1

38.1±1.9

3236±547

12.2±4.1

371(42.6)

362(41.5)

139 (15.9)

4.7±0.5

10.8±1.0

9.4±1.1

37.7±1.8

3348±615

12.2±3.7

104(45.2)

68(29.6)

58(25.2)

5.7±0.7

11.9±1.4

10.5±1.6

“—”:无相关数据. * 与一项异常孕妇比较, P <0.017; # 与二项异常孕妇比较, P <0.017.BMI:身体质量指数;OGTT :口服葡萄糖耐量试验.

2.2不同 OGTT 异常项数孕妇不良妊娠结局比较

OGTT 三项指标均异常的孕妇妊娠期高血压疾病、早产、巨大胎儿和 LGA 发生率均高于一项和二项指标异常的孕妇(均 P <0.017);二项指标异常的孕妇妊娠期高血压疾病和早产发生率高于 一项指标异常的孕妇(均 P <0.017),见 表 2 。结果提示, GDM 孕妇 OGTT 血糖异常项数越多,不良妊娠结局发生风险越大。 不同口服葡萄糖耐量试验异常项数孕妇不良妊娠结局比较 Table 2 Comparison of adverse pregnancy outcomes among groups with different numbers of abnormal blood glucose items in OGTT n (%)]

妊娠期高血压疾病

大于胎龄儿

小于胎龄儿

103 (6.82)

158 (10.47)

85 (5.63)

103 (6.82)

323 (21.40)

58 (3.84)

89 (10.20)

120 (13.76)

59 (6.77)

69 (7.91)

194 (22.25)

38 (4.36)

41 (17.83)

45 (19.57)

30 (13.04)

20 (8.70)

78 (33.91)

6 (2.61)

“—”:无相关数据. * 与一项指标异常孕妇比较, P <0.017; # 与二项指标异常孕妇比较, P <0.017.

2.3不同孕期增重孕妇不良妊娠结局比较

孕期增重过多孕妇妊娠期高血压疾病、巨大胎儿、LGA 发生率明显高于增重不足和增重适宜孕妇,早产、低体重儿发生率显著高于增重适宜孕妇(均 P <0.017);增重不足孕妇早产、低体重儿、SGA 发生率显著高于增重适宜孕妇,巨大胎儿发生率明显低于增重适宜孕妇(均 P <0.017),见 表 3 。结果提示,GDM 孕妇孕期增重不足或过度均可增加不良妊娠结局的发生风险。 孕期不同程度增重孕妇不良妊娠结局比较 Table 3 Comparison of adverse pregnancy outcomes among different gestational weight gain groups n (%)]

妊娠期高血压疾病

大于胎龄儿

小于胎龄儿

59 (5.92)

156 (15.65)

37 (3.71)

99 (9.93)

193 (19.36)

55 (5.52)

92 (7.99)

105 (9.11)

71 (6.16)

61 (5.30)

233 (20.23)

30 (2.60)

82 (17.75)

62 (13.42)

66 (14.29)

32(6.93)

169 (36.58)

17 (3.68)

“—”:无相关数据. * 与增重不足孕妇比较, P <0.017; # 与增重适宜孕妇比较, P <0.017.

2.4OGTT 异常项数及孕期增重与不良妊娠结局叉生分析结果

OGTT 一项指标异常的孕妇中,校正比值比后孕期增重不足是发生早产、低体重儿的危险因素,是LGA的保护因素;孕期增重过多则是妊娠期高血压疾病、早产、低体重儿的危险因素。OGTT二项指标异常的孕妇中,孕期增重不足是巨大胎儿和 LGA 的保护因素;增重过多是早产发生的危险因素。OGTT 三项指标均异常的孕妇中,孕期增重与不良妊娠结局的发生无明显关联( 表 4 )。结果提示,不同 OGTT 血糖异常项数的 GDM 孕妇孕期增重与不良妊娠结局的相关性不同。 口服葡萄糖血糖试验异常项数及孕期增重与不良妊娠结局叉生分析结果 Table 4 Cross-proliferation analysis of gestational weight gain and adverse pregnancy outcome among groups of different OGTT blood glucose abnormal items

妊娠期高血压疾病

大于胎龄儿

小于胎龄儿

0.33~1.32

1.10~2.52

0.51~1.53

1.07~4.53

0.27~0.59

1.03~3.43

1.35~3.41

1.20~2.72

0.83~2.59

1.10~4.30

0.83~1.51

0.23~1.75

0.28~1.07

0.51~1.54

0.09~0.67

0.95~6.10

0.34~0.86

0.93~4.09

0.88~2.62

1.23~3.18

0.98~3.82

0.72~4.11

0.91~2.05

0.41~2.72

0.31~2.28

0.39~2.61

0.64~1.32

0.22~3.30

0.34~1.61

0.16~42.83

0.71~3.12

0.90~3.78

0.49~2.51

0.49~3.63

0.61~2.06

0.67~55.78

“—”:无相关数据; P <0.05.

3讨论

随着生活水平的提高和饮食结构的改变,GDM 发病率呈逐年上升趋势。近年来我国 GDM 发病率已上升至 17.5% ,患者围产期并发症的发生也随之增加。本研究对 2611 例 GDM 孕妇进行了分层分析,结果显示随着 GDM 孕妇的 OGTT 异常项数增多,其发生妊娠期高血压疾病、早产、巨大胎儿、LGA 的风险明显增加。孕期增重过多或过少均可引起妊娠不良结局。在 OGTT 异常项目数与孕期增重关系的分层分析中发现,孕期增重与不良妊娠结局的关联随着 OGTT异常项数的增加而减弱,提示两者与妊娠结局的关联存在交互作用。

不良妊娠结局的发生风险随着 OGTT 异常项数增加而升高。Feng 等 发现,OGTT 异常项数与剖宫产、早产以及新生儿并发症的发生风险呈正相关,OGTT 异常项数越多,发生不良妊娠结局的风险越大。Zhou 等 也提出,随着 OGTT 异常项目增加,LGA、新生儿低血糖发生率上升。分析原因可能与二项或三项血糖异常孕妇的葡萄糖代谢平衡和胰岛素敏感性破坏相关

研究显示,孕期体重增长是影响孕妇血糖水平的一项重要因素,尤其增重超过美国医学研究院标准可增加发生 GDM 风险 。孕期增重过多导致胰岛素抵抗增加,胰岛β细胞耗竭,使β细胞无法分泌足够的胰岛素来代偿妊娠引起的胰岛素抵抗,从而导致 GDM 的发生。GDM 孕妇孕期增重越多,其发生妊娠期高血压疾病、巨大胎儿、胎儿窘迫等的风险也明显增加 。一项纳入 23 篇文献涉及 130 余万例孕妇的荟萃分析发现 ,妊娠期增重不足和增重过多分别占 23%和 47%,增重不足与 SGA、早产风险增加有关,分别为增重适宜的 1.53、1.70 倍;增重过多与 LGA、巨大胎儿和剖宫产风险增加有关,分别为增重适宜的 1.85、1.95、1.30 倍。Mastella 等 研究发现,孕期增重过多是 LGA 的独立危险因素。Hu 等 研究发现,孕期增重不足与早产风险增加显著相关。研究发现,孕期增重与早产呈“U”形非线性剂量反应关系,增重不足及增重过多均是早产的独立危险因素 。孕期增重与低体重儿发生率也呈不对称的“U”形,增重极端不足及过多均可引起低出生体重 。低体重儿可能与孕期营养摄入、增重不合理造成代谢紊乱,引起母体胎盘血流动力学改变,影响胎盘发育和胎盘转运功能有关。妊娠期高血压疾病可能与孕期增重过多,组织间液体潴留,导致肾素–血管紧张素–醛固酮系统的平衡失调有关。早产可能与妊娠期并发症如妊娠期高血压疾病等有关。本文资料中,孕期增重过多孕妇发生妊娠期高血压疾病、巨大胎儿、LGA 风险明显高于孕期增重不足及增重适宜孕妇,增重不足及增重过多孕妇发生早产及低体重儿风险均高于增重适宜孕妇。

本研究还发现,OGTT 一项异常的孕妇孕期增重不足或过多与多项不良妊娠结局相关,但 OGTT 三项异常的孕妇孕期增重与不良妊娠结局无明显相关。原因如下:相比孕期增重因素,孕妇糖代谢异常程度在发生不良妊娠结局中起主导作用,OGTT 一项异常的孕妇葡萄糖代谢及胰岛素敏感性尚未严重破坏,孕期不合理增重对胰岛素分泌和抵抗产生影响,造成血糖波动,从而发生不良妊娠结局风险;而OGTT三项异常的孕妇糖耐量受损严重,胰岛素分泌及储存均受到破坏,仅通过孕期体重管理减少不良妊娠结局发生风险效果不理想。

综上所述,随着 OGTT 异常项数增多,不良妊娠结局的风险逐层上升;孕期不合理增重可增加不良妊娠结局风险。同时在 GDM 孕期管理中,对于 OGTT 一项或二项升高孕妇,需更加注重孕期体重管理,减少孕期不合理增重对妊娠结局的不良影响;而针对三项均升高的 GDM 孕妇,需更加注重严格的血糖监测并采取药物降糖等积极干预措施以预防不良妊娠结局发生。本研究仍存在一些不足之处:第一,本研究孕妇孕前体重及孕期增重等数据是通过回顾性方式收集的,可能存在回忆偏倚;第二,本研究仅考虑孕期总增重对妊娠结局的影响,需进一步研究不同妊娠阶段增重对 GDM孕妇妊娠结局的影响;第三,本研究对象来自单中心,可能存在样本代表性偏倚。

Funding Statement

国家自然科学基金 (81974234);浙江省重点研发计划 (2018C03010)

COMPETING INTERESTS

所有作者均声明不存在利益冲突

References

2. Hapo Study Cooperative Research Group. METZGER B E, LOWE L P, DYER A R, et al. Hyperglycemia and adverse pregnancy outcomes[J] N Engl J Med . . 2008; 358 (19):1991–2002. doi: 10.1056/NEJMoa0707943. [ PubMed ] [ CrossRef ] [ Google Scholar ]
4. LINNENKAMP U, GUARIGUATA L, BEAGLEY J, et al. The IDF diabetes atlas methodology for estimating global prevalence of hyperglycaemia in pregnancy[J] Diabetes Res Clin Pract . . 2014; 103 (2):186–196. doi: 10.1016/j.diabres.2013.11.004. [ PubMed ] [ CrossRef ] [ Google Scholar ]
5. 陈海天, 李珠玉, 刘培培, 等. 广州地区妊娠期糖尿病发病情况调查及妊娠结局分析[J]. 中国慢性病预防与控制 , 2017, 25(1): 38-41 CHEN Haitian, LI Zhuyu, LIU Peipei, et al. Investigation on the incidence and outcome of gestational diabetes mellitus in Guangzhou[J]. Chinese Journal of Prevention and Control of Chronic Diseases , 2017, 25(1): 38-41. (in Chinese)
6. 陈晓璐, 彭洋颖, 徐雪清. 妊娠不同时期体质量增长与妊娠结局关系的研究[J]. 中华医学杂志 , 2018, 98(19): 1493-1497 [ PubMed ] CHEN Xiaolu, PENG Yangying, XU Xueqing. Study on weight gain in different stages of pregnancy and pregnancy outcomes[J]. National Medical Journal of China , 2018, 98(19): 1493-1497. (in Chinese) [ PubMed ]
7. 张亦奇, 兰茜, 张琚, 等. 孕期总增重与不良妊娠结局关系的前瞻性研究[J]. 中华流行病学杂志 ,2018, 39(12): 1626-1629 [ PubMed ] ZHANG Yiqi, LAN Qian, ZHANG Ju, et al. Association between gestational weight gain and adverse pregnancy outcomes: a prospective study[J]. Chinese Journal of Epidemiology , 2018, 39(12): 1626-1629. (in Chinese) [ PubMed ]
8. 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会妊娠合并糖尿病协作组. 妊娠合并糖尿病诊治指南 (2014)[J]. 中华围产医学杂志 , 2014, 17(8): 537‑545 Obstetrics Division, Obstetrics and Gynecology Branch, Chinese Medical Association, Cooperative Group of Pregnancy with Diabetes, Chinese Society of Perinatology. Guidelines for the management of gestational diabetes mellitus(2014)[J]. Chinese Journal of Perinatal Medicine , 2014, 17(8): 537‑545. (in Chinese)
9. Institute of Medicine and National Research Council Committee to Reexamine IOM Pregnancy Weight Guidelines. Weight gain during pregnancy: reexamining the guidelines [M]. Washington: National Academies Press, 2009 [ PubMed ]
10. 谢幸, 孔北华, 段涛, 等. 妇产科学 [M]. 9 版. 北京: 人民卫生出版社, 2018: 83-137 XIE Xing, KONG Beihua, DUAN Tao, et al. Obstetrics and gynecology [M]. 9th ed. Beijing: People’s Medical Publishing House, 2018: 83-137. (in Chinese)
11. ZHU W W, YANG H X, WEI YM, et al. Evaluation of the value of fasting plasma glucose in the first prenatal visit to diagnose gestational diabetes mellitus in China[J]. Diabetes Care , 2013, 36(3): 586‑590 [ PMC free article ] [ PubMed ]
12. FENG H, ZHU W W, YANG H X, et al. Relationship between oral glucose tolerance test charactedstics and adverse pregnancy outcomes among women with gestational diabetes mellitus[J] Chin Med J (Engl) . 2017; 130 (9):1012–1018. doi: 10.4103/0366-6999.204928. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
13. ZHOU J L, XING J, LIU C H, et al. Effects of abnormal 75 g oral glucose tolerance test at different time points on neonatal complications and neurobehavioral development in the pregnant women with gestational diabetes mellitus (a STROBE-compliant article)[J/OL] Medicine (Baltimore) . 2018; 97 (21):e10743. doi: 10.1097/MD.0000000000010743. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
14. 高云鹤, 郑海清, 殷彩欣, 等. 妊娠期糖尿病患者糖化血红蛋白及血糖指标异常与妊娠结局的相关性[J]. 实用妇产科杂志 , 2019, 35(3): 228-233 [ PubMed ] GAO Yunhe, ZHENG Haiqing, YIN Caixin, et al. The association between mid-pregnancy glucose levels and pregnancy outcome mellitus[J]. Journal of Practical Obstetrics and Gynecology , 2019, 35(3): 228-233. (in Chinese)
15. 梁一, 李丹婷, 陈梦雪, 等. 中国西南地区妇女孕前体质量指数、孕期增重与妊娠期糖尿病关系的前瞻性队列研究[J]. 四川大学学报(医学版) , 2019, 50(1): 83-87 [ PubMed ] LIANG Yi, LI Danting, CHEN Mengxue, et al. Associations of pre-pregnancy body mass index and gestationaI weight gain with gestational diabetes meIlitus: a cohort study in southwest China[J]. Journal of Sichuan University(Medical Science Edition) , 2019, 50(1): 83-87. (in Chinese) [ PubMed ]
17. 王雪影, 周莉. 妊娠期糖尿病患者孕前体重指数及孕期体重增加量与妊娠结局及产科并发症关系研究[J]. 中国实用妇科与产科杂志 , 2020, 36(8): 757-761 WANG Xueying, ZHOU Li. Relationship of pre-pregnancy body mass index and gestational weight gain with obstetric complications and pregnancy outcome in patients with gestational diabetes mellitus[J]. Chinese Journal of Practical Gynecology and Obstetrics , 2020, 36(8): 757-761. (in Chinese)
18. GOLDSTEIN R F, ABELL S K, RANASINHA S, et al. Association of gestational weight gain with maternal and infant outcomes: a systematic review and meta-analysis[J] JAMA . . 2017; 317 (21):2207–2225. doi: 10.1001/jama.2017.3635. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
19. MASTELLA L S, WEINERT L S, GNIELKA V, et al. Influence of maternal weightgain birthweight: agestational diabetes cohort[J]. Arch Endocrinol Metab , 2018, 62(1): 55-63 [ PMC free article ] [ PubMed ]
20. HU Y, WU Q, HAN L, et al. Association between maternal gestational weight gain and preterm birth according to body mass index and maternal age in Quzhou, China[J] Sci Rep . . 2020; 10 (1):15863. doi: 10.1038/s41598-020-72949-w. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
21. 张丹丹, 谈迪心, 王斌, 等. 孕期增重与早产关联的流行病学分析[J]. 中华流行病学杂志 , 2016, 37(7): 1012-1016 [ PubMed ] ZHANG Dandan, TAN Dixin, WANG Bin, et al. Association between gestational weight gain and preterm birth: a retrospective epidemiological analysis in Wuhan[J]. Chinese Journal of Epidemiology , 2016, 37(7): 1012-1016. (in Chinese) [ PubMed ]
22. 李艳华, 陈小梅, 陈水仙, 等. 孕前体重和孕期增重对新生儿出生结局及孕产妇围产结局的影响[J]. 中华流行病学杂志 , 2014, 35(6): 635-640 [ PubMed ] LI Yanhua, CHEN Xiaomei, CHEN Shuixian, et al. A cohort study on the impacts of pre-pregnancy maternal body mass index, gestational weight gain on neonate birth status and perinatal outcomes in Fujian province[J]. Chinese Journal of Epidemiology , 2014, 35(6): 635-640. (in Chinese) [ PubMed ]

Articles from Journal of Zhejiang University (Medical Sciences) are provided here courtesy of Zhejiang University Press